Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration.
about
A P2X receptor-mediated nociceptive afferent pathway to lamina I of the spinal cordNociceptive transmission and modulation via P2X receptors in central pain syndromePotential for developing purinergic drugs for gastrointestinal diseasesP2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATPIn pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.The h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.Endosome-mediated retrograde axonal transport of P2X3 receptor signals in primary sensory neuronsNav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation.Sensitization of cutaneous neuronal purinergic receptors contributes to endothelin-1-induced mechanical hypersensitivityNeuromodulation by extracellular ATP and P2X receptors in the CNS.Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord.P2X receptors in sensory neurons co-cultured with cancer cells exhibit a decrease in opioid sensitivity.P2X receptors: New players in cancer pain.Air-stimulated ATP release from keratinocytes occurs through connexin hemichannels.Estrogen modulation of peripheral pain signal transduction: involvement of P2X(3) receptors.Mechanisms underlying purinergic P2X3 receptor-mediated mechanical allodynia induced in diabetic ratsSensitization of P2X3 receptors by cystathionine β-synthetase mediates persistent pain hypersensitivity in a rat model of lumbar disc herniation.Purinoceptors as therapeutic targets for lower urinary tract dysfunction.Translocation of neuronal nitric oxide synthase to the plasma membrane by ATP is mediated by P2X and P2Y receptors.Localization of P2X2 and P2X3 receptors in rat trigeminal ganglion neurons.Functional genomics to new drug targets.Prostaglandin E2 potentiation of P2X3 receptor mediated currents in dorsal root ganglion neuronsNew targets for neuropathic pain therapeutics.Differential expression of ATP-gated P2X receptors in DRG between chronic neuropathic pain and visceralgia rat models.RNA interference in pain research.Purinergic receptors as potential therapeutic targets in Alzheimer's disease.Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.Modulation of P2X3 and P2X2/3 Receptors by Monoclonal AntibodiesRho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats.P2X receptor-mediated purinergic sensory pathways to the spinal cord dorsal horn.P2 receptors and chronic painSustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors.P2X receptor antagonists for pain management: examination of binding and physicochemical properties.Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.P2X3 and P2X2/3 receptor antagonists.Calcium-permeable ion channels in pain signaling.Investigation into the role of P2X(3)/P2X(2/3) receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological studyP2X3 antagonists: novel therapeutics for afferent sensitization and chronic pain.siRNA relieves chronic neuropathic painP2X7 receptor blockade reverses purinergic facilitation of neck muscle nociception in mice.
P2860
Q24806550-6AF60081-60F1-4D91-BFB7-4E38A19F5C72Q26745701-FB7862BB-466E-4EE8-A0A6-3575C585A0B1Q27000719-4C959280-77F1-4F5F-8EA8-15261C6AF247Q28585703-6C2A0FCC-32BA-477E-A48D-720C044A866DQ30409620-BD8FA24E-D975-4174-87DF-70D20E2560C9Q30428280-FF6FE294-AD34-47D7-BAFA-F15F3E21FC12Q30512460-7353E835-BEEC-40EC-B17C-3901DA187E1AQ31029732-2E94CA9A-64DB-4605-AB45-8B192EF65C46Q33573737-9BEF9650-55FF-46C6-848C-54AFBED2CFD8Q33781729-4552F5E1-863A-4C00-9BB7-852856CCF9BDQ33898994-D7758383-BAA8-4DD0-8C7E-BC9971DCEA5DQ33920284-27FDA01A-3ADD-41E4-BCEC-4CA17FEF55E1Q34567944-E5240A83-99CC-4674-A165-CC3BCC7B324AQ34607032-96FDA555-8436-4A62-961B-2E21A437C22AQ34868452-0E778B6C-2E53-4CE2-A2BA-8594B78DEB55Q35200553-311C4313-D04C-4D27-B296-27DADB14CCC2Q35213527-6B738F78-D405-4D64-9708-A884D85A2EF0Q35545723-E05B3077-BA38-4BAF-8A75-6DDF04246C7BQ35575422-CD030BCE-02EB-4BDE-868D-063E409B7485Q35774516-78F7983F-4A78-41D8-A274-7994D8BFCDEFQ35936438-0D56E801-6D7C-4C97-B2E6-8DE66CEA408EQ36116683-D0F44C0B-0730-4E03-AC1A-FF38662CBD36Q36219689-913041EB-82AF-4A19-89B7-FEA32CA1D519Q36568417-A25C3D5C-AC81-4015-8D69-6CB384ACE3ABQ36618289-E3A528D9-CD4A-462C-A059-5EDC7A2D74E2Q36844881-862479A3-09DC-4F43-83FC-D43F747EC40CQ36927755-2D304481-5748-4579-9B26-D09C09E9C81EQ37066034-1E95527D-62CF-4F0F-A53B-C84EB0F9FDFCQ37115753-595A4FB0-17E6-4F44-A2C5-F22C141A6A34Q37135470-8EF03572-2932-4F89-98DA-D5DAE1AF2409Q37135497-3DBC1ADE-80B1-416A-96D1-0942334CD4DDQ37391889-E87D16D1-3D00-4F85-9054-32525453AB2CQ37956570-71BDEE69-D4C3-4E63-85CF-86939C322828Q38056397-1DC06887-E070-49FE-96A9-CE7A8069284DQ38172655-29460182-0ACE-4306-9DC7-0A49E1A89568Q38175134-853AEFBC-9E43-4DC4-92C1-4636B3C79073Q38758277-F80181BB-9E2C-4465-8729-EA221FCC1803Q39248588-EB9B32B9-D250-409F-A68A-B61F68DDAE05Q39383106-C77CE3F1-B71F-40B9-8B75-10891F3D9A4BQ39625542-1BE51A45-8B67-430D-8077-756FE81E4836
P2860
Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of A-317491, a novel a ...... d intraplantar administration.
@en
Effects of A-317491, a novel a ...... d intraplantar administration.
@nl
type
label
Effects of A-317491, a novel a ...... d intraplantar administration.
@en
Effects of A-317491, a novel a ...... d intraplantar administration.
@nl
prefLabel
Effects of A-317491, a novel a ...... d intraplantar administration.
@en
Effects of A-317491, a novel a ...... d intraplantar administration.
@nl
P2093
P2860
P356
P1476
Effects of A-317491, a novel a ...... d intraplantar administration.
@en
P2093
Carol T Wismer
Chang Z Zhu
Chih-Hung Lee
Connie R Faltynek
Joseph Mikusa
Katharine L Chu
Michael F Jarvis
Prisca Honore
Steve McGaraughty
P2860
P304
P356
10.1038/SJ.BJP.0705574
P407
P577
2003-11-17T00:00:00Z